Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

Neurology

Volumn 65, Issue 6, 2005, Pages 802-806

  Sandberg Wollheim, Magnhild ^a   Frank, D ^b   Goodwin, T M ^d   Giesser, B ^e   Lopez Bresnahan, M ^b   Stam Moraga, M ^c   Chang, P ^b   Francis, G S ^b   Gardner, Jason ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b EMD SERONO INC   (United States)

^c Serono   (Switzerland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ABORTION; ADULT; ARTICLE; CLINICAL TRIAL; CONGENITAL MALFORMATION; DRUG SAFETY; DRUG WITHDRAWAL; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; FETOTOXICITY; FETUS DEATH; FOLLOW UP; HUMAN; HYDROCEPHALUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PREGNANCY COMPLICATION; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL;

EID: 25444458822     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000168905.97207.d0     Document Type: Article

References (36)

1. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
2. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study 1. Clinical course and disability. Brain 1989;112:133-146.
5. Mueller BA, Zhang J, Critchlow CW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol 2002;186:446-452.
6. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59:1496-1506.
7. Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study. Neurology 1999;53:679-686.
8. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258.
9. Mikol D, Burns T, Bennett S, Lopez-Bresnahan M. Patterns of MS treatment with disease modifying therapies before entry into an open-label clinical trial of Rebif injections. Mult Scler 2002;8:S88-S89. Abstract.
10. Paty DW. Long-term observational efficacy and safety follow-up of the PRISMS cohort. Mult Scler 2003;9:S138-S139.
11. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
12. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706-710.
13. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
14. Hill JA. Miscarriage risk factors and causes: what we know now. OBG Management 1998;58-70.
15. Lewis V. The biology of early pregnancy loss. In: Woods JR Jr, Woods JLE, eds. Loss during pregnancy or in the newborn period. Pitman, NJ: Jannetti Publications, 1997:37-69.
16. Scott JR. Early pregnancy loss. In: Danforth DN, De Saia PJ, Hammond CB, Spellacy WN, eds. Danforth's obstetrics & gynecology. Philadelphia, PA: Lippincott, Williams & Wilkins, 1999:143-153.
17. National Center for Health Statistics, National Vital Statistics System. Infant Mortality Rates, Fetal Mortality Rates, and Perinatal Mortality Rates, According to Race: United States, Selected Years 1950-2001. Atlanta: Centers for Disease Control and Prevention; 2003.
18. Hiratsuka M, Minakami H, Koshizuka S, Sato I. Administration of interferon-alpha during pregnancy: effects on fetus. J Perinat Med 2000;28:372-376.
19. Milano V, Gabrielli S, Rizzo N, et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha-2a. J Matern Fetal Med 1996;5:74-78.
20. Kuroiwa M, Gondo H, Ashida K, Kamimura T, Miyamoto T, Niho Y. Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy. Am J Hematol 1998;59:101-102.
21. Baykal C, Zengin N, Coskun F, Guler N, Ayhan A. Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report. Eur J Gynaecol Oncol 2000;21:89-90.
22. Mubarak AA, Kakil IR, Awidi A, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 2002;69:115-118.
23. Koh LP, Devendra K, Tien SL. Four pregnancies in two patients with essential thrombocythaemia- a case report. Ann Acad Med Singapore 2002;31:353-356.
24. Cincotta R, Higgins JR, Tippett C, et al. Management of essential thrombocythaemia during pregnancy. Aust N Z J Obstet Gynaecol 2000;40:33-37.
25. Schmidt HH, Neumeister P, Kainer F, Karpf EF, Linkesch W, Sill H. Treatment of essential thrombocythemia during pregnancy: antiabortive effect of interferon-alpha? Ann Hematol 1998;77:291-292.
26. Trotter JF, Zygmunt AJ. Conception and pregnancy during interferon-alpha therapy for chronic hepatitis C. J Clin Gastroenterol 2001;32:76-78.
27. Ferrari VD, Jirillo A, Lonardi F, Pavanato G, Bonciarelli G. Pregnancy during alpha-interferon therapy in patients with advanced Hodgkin's disease. Eur J Cancer 1995;31A:2121-2122.
28. Shiraki K, Moriwaki M, Ataka S, Henmi K, Miki T, Kanaoka Y. Acute retinal necrosis late in the second trimester. Am J Ophthalmol 1998;125:103-104.
29. Echols KT, Gilles JM, Diro M. Mycosis fungoides in pregnancy: remission after treatment with alpha-interferon in a case refractory to conventional therapy: a case report. J Matern Fetal Med 2001;10:68-70.
30. Challier JC, Guerre-Millo M, Nandakumaran M, Gerbaut L, d'Athis P. Clearance of compounds of different molecular size in the human placenta in vitro. Biol Neonate 1985;48:143-148.
31. Waysbort A, Giroux M, Mansat V, Teixeira M, Dumas JC, Fuel J. Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrob Agents Chemother 1993;37:1232-1237.
32. Pons J-C, Lebon P, Frydman R, Delfraissy J-F. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995;10:7-10.
33. Iles RK, Chard T. Enhancement of ectopic beta-human chorionic gonadotrophin expression by interferon-alpha. J Endocrinol 1989;123:501-507.
34. Chard T. Interferon in pregnancy. J Dev Physiol 1989;11:271-276.
35. Duc-Goiran P, Robert-Galliot B, Lopez J, Chany C. Unusual apparently constitutive interferons and antagonists in human placental blood. Proc Natl Acad Sci U S A 1985;82:5010-5014.
36. Coyle PK, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003;60:A60.